uniQure N.V. Cash and Restricted Cash
uniQure N.V. (QURE) had Cash and Restricted Cash of $141.54 million as of 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-05-05
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $141.54M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $81.80M; Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed $81.80M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $598.55M.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $255.27M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-03-31 | $141.54M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $81.80M 10-Q · filed 2026-05-05 | $81.80M 10-K · filed 2026-03-02 |
| 2025-09-30 | $598.55M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $255.27M 10-Q · filed 2025-07-29 | |
| 2025-03-31 | $218.66M 10-Q · filed 2026-05-05 | |
| 2024-12-31 | $160.33M 10-Q · filed 2026-05-05 | |
| 2024-09-30 | $253.08M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $291.04M 10-Q · filed 2025-07-29 | |
| 2024-03-31 | $246.23M 10-Q · filed 2025-05-09 | |
| 2023-12-31 | $244.54M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $232.64M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $516.77M 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $157.02M 10-Q · filed 2024-05-07 | |
| 2022-12-31 | $231.17M 10-K · filed 2026-03-02 | |
| 2022-09-30 | $443.42M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $503.67M 10-Q · filed 2023-08-01 | |
| 2022-03-31 | $528.08M 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $559.35M 10-K · filed 2025-02-27 | |
| 2021-09-30 | $581.27M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $680.16M 10-Q · filed 2022-08-08 | |
| 2021-03-31 | $263.53M 10-Q · filed 2022-05-02 | |
| 2020-12-31 | $247.68M 10-K · filed 2024-02-28 | |
| 2020-09-30 | $282.21M 10-Q · filed 2021-10-25 | |
| 2020-06-30 | $316.95M 10-Q · filed 2021-07-26 | |
| 2020-03-31 | $344.95M 10-Q · filed 2021-05-10 | |
| 2019-12-31 | $380.73M 10-K · filed 2023-02-27 | |
| 2019-09-30 | $406.08M 10-Q · filed 2020-10-27 | |
| 2019-06-30 | $187.03M 10-Q · filed 2020-07-30 | |
| 2019-03-31 | $211.72M 10-Q · filed 2020-04-29 | |
| 2018-12-31 | $237.34M 10-K · filed 2022-02-25 | |
| 2018-09-30 | $242.00M 10-Q · filed 2019-10-28 | |
| 2018-06-30 | $261.64M 10-Q · filed 2019-07-29 | |
| 2018-03-31 | $143.32M 10-Q · filed 2019-04-29 | |
| 2017-12-31 | $161.85M 10-K · filed 2021-03-01 | |
| 2017-09-30 | $91.40M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $105.97M 10-Q · filed 2018-08-08 | |
| 2017-03-31 | $122.11M 10-Q · filed 2018-04-30 | |
| 2016-12-31 | $134.32M 10-K · filed 2020-03-02 | |
| 2015-12-31 | $222.87M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |